Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial
Open Access
- 8 February 2024
- journal article
- research article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (3) , 00750-2023
Abstract
Background: In China, the prevalence of severe asthma with eosinophilic phenotype is rising, yet treatment options are limited. Mepolizumab is the first targeted biologic therapy for eosinophilic-driven disease in China. This study (clinicaltrials.gov identifierNCT03562195) evaluated efficacy and safety of mepolizumab in Chinese patients with severe asthma.Methods: The phase III, multicentre, randomised, placebo-controlled, double-blind, parallel-group study enrolled patients aged ≥12 years with severe asthma, with two or more exacerbations in the previous year, and on inhaled corticosteroids plus at least one controller medication. Following a 1–4-week run-in, patients were randomised 1:1 to mepolizumab 100 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end-point was annualised rate of clinically significant exacerbations (CSEs) through week 52. Secondary end-points were time to first CSE, frequency of CSEs requiring hospitalisation/emergency department visits or hospitalisation over 52 weeks, mean change in St George's Respiratory Questionnaire (SGRQ) total score and pre-bronchodilator forced expiratory volume in 1 s (FEV1) at week 52; safety was evaluated.Results: The modified intention-to-treat population included 300 patients. At week 52 with mepolizumabversusplacebo, annualised rate of CSEs was 65% lower (0.45versus1.31 events per year; rate ratio 0.35, 95% CI 0.24–0.50; p1increased (p=0.006). Incidence of adverse events was similar between treatment groups.Conclusion: Mepolizumab provided clinical benefits to patients with severe asthma in China and showed a favourable benefit–risk profile.Keywords
Funding Information
- GlaxoSmithKline (GSK ID: 201536)
This publication has 29 references indexed in Scilit:
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEuropean Respiratory Journal, 2012
- CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trialsJournal of Pharmacology and Pharmacotherapeutics, 2010
- Asthma: defining of the persistent adult phenotypesThe Lancet, 2006
- Interleukin-5 Induces CD34+ Eosinophil Progenitor Mobilization and Eosinophil CCR3 Expression in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Proceedings of the ATS Workshop on Refractory AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils.1991